Sanofi acquiring Bioverativ for $11.6B

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11

Read the full 327 word article

User Sign In